Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer

Fig. 3

Molecular profiling by PTC-MA in primary and lymph node metastatic PTCs. a Driving lesions by PTC-MA in patients with multiple tumor specimens. Color code: light blue, BRAFV600E; green, gene fusions; pink, pTERT mutations; grey, Wild Type (WT) for PTC-MA assay; purple BRAV600E+ pTERT mutation; white, not available (NA) tissue. Detailed mutation/gene fusion description on the right. b Driving lesions by PTC-MA in the 39 PTC tissues investigated by gene/miRNA microarrays. Samples were stratified according to tissue type and patient RAI class. Data are shown as percentages; the corresponding sample numbers are indicated in the bars. The total number of samples for each class is indicated in brackets. Abbreviations: RAI, radioiodine; synLNM, synchronous lymph node metastasis; LNM post RAI, lymph node metastasis diagnosed and collected after RAI; RAI+/D+, RAI uptake at the metastatic site and disease persistence; RAI−/D+, no RAI uptake at the metastatic site and disease persistence; RAI+/D-, RAI uptake at the metastatic site and disease remission

Back to article page